PMID- 24397777
OWN - NLM
STAT- MEDLINE
DCOM- 20150803
LR  - 20151119
IS  - 1476-4954 (Electronic)
IS  - 1476-4954 (Linking)
VI  - 27
IP  - 17
DP  - 2014 Nov
TI  - Effect of anti-vascular endothelial growth factor antibody during early fetal 
      development in rats.
PG  - 1744-8
LID - 10.3109/14767058.2013.879645 [doi]
AB  - OBJECTIVE: To examine the effect of anti-vascular endothelial growth factor 
      (VEGF) antibody Bevacizumab during early fetal development in rats. METHODS: 
      Presumed-pregnant rats received single intraperitoneal injection of Bevacizumab 
      (0-20 mg/kg) on gestational day (GD) 3, 7, and 14 (n = 2 rats/group). After Study 
      1 (dose range finding study), Study 2 performed with intraperitoneal 20 mg/kg 
      bevacizumab or saline on GD 7 (n = 6 rats/group including the Study 1). Blood 
      samples were collected 3 and 7 d after the injection. Uterus and ovarian tissues 
      were obtained 7 d after the injection. Number of gestational sacs (GS), size of 
      GS and fetus, serum rat beta chorionic gonadotropin (beta-CG), and platelet endothelial 
      cell adhesion molecule (PECAM) for immunohistochemical assessment of angiogenesis 
      were evaluated. RESULTS: Number of GS, size of GS, and fetus were lower in the 
      study group than the control group. Serum rat beta-CG levels were significantly 
      increased in the control group and significantly decreased in the study group. 
      Staining densities for PECAM in vascular structures in both corpus luteum and 
      placenta were lower in the study group than the control group. CONCLUSION: 
      Anti-VEGF antibody has an inhibitory effect on pregnancy development and caused 
      litter death.
FAU - Kaygusuz, Ikbal
AU  - Kaygusuz I
AD  - Department of Obstetrics and Gynecology .
FAU - Eser, Ayla
AU  - Eser A
FAU - Inegol Gumus, Ilknur
AU  - Inegol Gumus I
FAU - Kosus, Aydin
AU  - Kosus A
FAU - Yenidunya, Sibel
AU  - Yenidunya S
FAU - Namuslu, Mehmet
AU  - Namuslu M
FAU - Kafali, Hasan
AU  - Kafali H
LA  - eng
PT  - Journal Article
DEP - 20140130
PL  - England
TA  - J Matern Fetal Neonatal Med
JT  - The journal of maternal-fetal & neonatal medicine : the official journal of the 
      European Association of Perinatal Medicine, the Federation of Asia and Oceania 
      Perinatal Societies, the International Society of Perinatal Obstetricians
JID - 101136916
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Chorionic Gonadotropin)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal, Humanized/*pharmacology
MH  - Bevacizumab
MH  - Chorionic Gonadotropin/blood
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Fetal Development/*drug effects
MH  - Fetus/drug effects
MH  - Gestational Age
MH  - Litter Size/drug effects
MH  - Placenta/drug effects
MH  - Pregnancy
MH  - Rats
MH  - Rats, Wistar
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors/immunology
OTO - NOTNLM
OT  - Anti-angiogenic agent
OT  - anti-VEGF antibody
OT  - bevacizumab
OT  - fetal development
OT  - rat
EDAT- 2014/01/09 06:00
MHDA- 2015/08/04 06:00
CRDT- 2014/01/09 06:00
PHST- 2014/01/09 06:00 [entrez]
PHST- 2014/01/09 06:00 [pubmed]
PHST- 2015/08/04 06:00 [medline]
AID - 10.3109/14767058.2013.879645 [doi]
PST - ppublish
SO  - J Matern Fetal Neonatal Med. 2014 Nov;27(17):1744-8. doi: 
      10.3109/14767058.2013.879645. Epub 2014 Jan 30.